94749-08-3 Salmeterol xinafoate AKSci V1621
 
 
Loading Please Wait...
  V1621    
Salmeterol xinafoate
, 98% (HPLC)
 
(±) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate




IDENTITY
CAS Number:94749-08-3
MDL Number:MFCD00897708
MF:C36H45NO7
MW:603.75
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Physical Form:White to off-white powder
Melting Point:124-142°C
Long-Term Storage:Store long-term at 2-8°C

BIOLOGICAL INFO
Solubility:MeOH
Application(s):beta2-adrenoceptor agonist

REVIEW

 Salmeterol xinafolate is a long-acting beta 2-adrenergic receptor agonist drug that is prescribed for the treatment of asthma and chronic obstructive pulmonary disease(COPD). Salmeterol xinafolate works as a typical beta 2-agonists, causing bronchodilation by relaxing the smooth muscle in the airway so as to treat the exacerbation of asthma. The long duration of action is due to Salmeterol xinafolate initially diffusing into the plasma membrane of the lung cells, and then slowly being released back outside the cell where they can come into contact with the beta-2 adrenoceptors, with the long carbon chain forming an anchor in the membrane. Salmeterol xinafolate is normally prescribed only for severe persistent asthma following previous treatment with a short-acting beta agonist such as salbutamol and is prescribed concurrently with a corticosteroid, such as beclometasone.

REFERENCES
[1]Johnson M. The pharmacology of salmeterol. Lung. 1990;168 Suppl:115-9
[2] Johnson M. Salmeterol: a novel drug for the treatment of asthma. Agents Actions Suppl. 1991;34:79-95.
[3] Jack D. The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor agonists. Br J Clin Pharmacol. 1991 May;31(5):501-14.
[4] Brogden RN, Faulds D. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 1991 Nov;42(5):895-912.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


RELATED PRODUCTS
K590Salmeterol
V1621Salmeterol xinafoate

Current as of March 22, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Adrenergic Agonists


PubChem
  @PubMed